Neil is a C-suite biotechnology executive and company board member with extensive experience in corporate development, deal-making, and IP strategy since 1997. His track record includes providing the core BD, licensing and IP expertise for significant venture capital financings, guiding multiple companies through successful IPOs, and negotiating strategic pharma and academic partnerships. In addition to his role at Eolo Pharma, he is Partner at Ventac Partners, CBO at the Italian venture builder Cube Labs, Interim CEO at Inhibitec in Spain, and Board Member at ArrayPatch in Ireland. He has also worked in two Swedish life science companies: as Chief Business Officer for Idogen AB and as IP Strategy Advisor to RhoVac AB. Previously, as Director of Business Development & IP at Genetrix Group, Spain, he managed IP and deal-making across its 10-company portfolio, leading the successful sale of Imbiosis to R-Biopharm. For the group’s lead company, Cellerix SA, he handled the IP diligence for two €27M VC rounds and a $40M licensing deal. The foundational IP he managed for Cellerix later supported a strategic merger with TiGenix NV, which culminated in a €520M acquisition by Takeda. His earlier experience includes serving as Director of IP & Technology at the Roche spin-out bioXell, Italy, contributing to three VC funding rounds totalling €50.5M, a $150M licensing deal with Merck & Co and the company’s successful IPO.